Jason Harris


Updated NCCN Guidelines Recommend Trastuzumab Deruxtecan, Sacituzumab Govitecan for Advanced Breast Cancer

July 04, 2022

The NCCN guidelines have been amended to include trastuzumab deruxtecan for use in patients with HER2-low metastatic breast cancer and sacituzumab govitecan for use in patients with triple-negative breast cancer or hormone receptor–positive, HER2-negative disease.

Patients With Treatment-Naïve RCC Achieve Superior QoL With Nivolumab/Cabozantinib

January 29, 2022

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.